Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2019
Reporting Period: Single event date (November 26, 2019)
The filing reports an unregistered sale of equity securities pursuant to a pre-existing letter agreement dated September 26, 2019.
Key Financial Metrics
This filing does not contain comprehensive financial statements (revenue, profit, cash flow, or margins). It reports a specific capital raise transaction:
- Funds Raised: $2.0 million
- Shares Issued: 1,369,863 shares of Class A common stock
- Price Per Share: $1.46
- Investor: MacAndrews & Forbes Group LLC
Debt, liquidity, and operating margin data are not provided in this document.
Material Changes
The material change reported is the execution of a capital raise under the September 2019 Letter Agreement. The Company exercised its right to require the Investor to purchase the specified shares, resulting in an immediate increase in cash and an increase in outstanding Class A common stock.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transaction was executed following the signing of definitive documentation. It references the September 2019 Letter Agreement (Exhibit 10.1 to the Q3 2019 10-Q) for full terms and conditions.
Outlook/Guidance: No forward-looking guidance or operational outlook is provided in this specific filing.
Risks/Contingencies: The filing notes that the disclosure is qualified in its entirety by reference to the underlying agreement.
Investor Verification Checklist
- Verify the terms of the September 26, 2019 Letter Agreement (Exhibit 10.1 to the Q3 2019 10-Q) to understand future purchase obligations or rights.
- Confirm the dilution impact of the 1,369,863 newly issued shares on existing shareholders.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not provide liquidity metrics.
- Check for any subsequent filings regarding the use of the $2.0 million proceeds.